Shenzhen YHLO Biotech Co., Ltd. (SHA:688575)
China · Delayed Price · Currency is CNY 14.17
+0.03 (0.21%)
At close: Mar 6, 2026
Shenzhen YHLO Biotech Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,809 | 1,974 | 2,018 | 3,930 | 1,134 |
Other Revenue | - | 37.93 | 34.69 | 51.13 | 44.37 |
| 1,809 | 2,012 | 2,053 | 3,981 | 1,178 | |
Revenue Growth (YoY) | -10.07% | -2.02% | -48.42% | 237.96% | 17.91% |
Cost of Revenue | - | 720.07 | 949.06 | 1,937 | 530.16 |
Gross Profit | 1,809 | 1,292 | 1,104 | 2,044 | 647.73 |
Selling, General & Admin | - | 607.43 | 565.36 | 617.71 | 296.87 |
Research & Development | - | 330.89 | 314.05 | 238.45 | 129.33 |
Other Operating Expenses | 1,699 | 7.2 | -34.82 | 30.2 | 8.09 |
Operating Expenses | 1,699 | 956.09 | 852.43 | 897.88 | 436.88 |
Operating Income | 110.4 | 335.46 | 251.62 | 1,146 | 210.85 |
Interest Expense | - | -12.18 | -6.25 | -8.41 | -11.22 |
Interest & Investment Income | - | 4.86 | 132.39 | 14.4 | 8.33 |
Currency Exchange Gain (Loss) | - | -0.73 | 3.06 | 9.71 | -2.76 |
Other Non Operating Income (Expenses) | -16.7 | -3.2 | -6.97 | -23.65 | -1.14 |
EBT Excluding Unusual Items | 93.71 | 324.19 | 373.85 | 1,138 | 204.06 |
Gain (Loss) on Sale of Investments | - | -31.52 | -32.73 | 54.45 | 0.15 |
Gain (Loss) on Sale of Assets | - | 1.82 | 2.79 | -3.39 | -0.2 |
Asset Writedown | - | -10.84 | -9.8 | -10.33 | - |
Other Unusual Items | - | 28.05 | - | 7.8 | 23.75 |
Pretax Income | 93.71 | 311.7 | 334.11 | 1,186 | 227.76 |
Income Tax Expense | 69.69 | 39.5 | 54.91 | 165.22 | 23.91 |
Earnings From Continuing Operations | 24.02 | 272.19 | 279.2 | 1,021 | 203.85 |
Minority Interest in Earnings | - | 29.34 | 75.81 | -9.15 | 0.9 |
Net Income | 24.02 | 301.53 | 355.01 | 1,012 | 204.75 |
Net Income to Common | 24.02 | 301.53 | 355.01 | 1,012 | 204.75 |
Net Income Growth | -92.03% | -15.06% | -64.92% | 394.33% | -2.75% |
Shares Outstanding (Basic) | 600 | 569 | 568 | 565 | 539 |
Shares Outstanding (Diluted) | 600 | 570 | 573 | 569 | 539 |
Shares Change (YoY) | 5.39% | -0.49% | 0.70% | 5.53% | 6.03% |
EPS (Basic) | 0.04 | 0.53 | 0.63 | 1.79 | 0.38 |
EPS (Diluted) | 0.04 | 0.53 | 0.62 | 1.78 | 0.38 |
EPS Growth | -92.45% | -14.54% | -65.17% | 368.42% | -8.28% |
Free Cash Flow | - | -63.41 | -735.9 | 1,018 | -113.04 |
Free Cash Flow Per Share | - | -0.11 | -1.28 | 1.79 | -0.21 |
Dividend Per Share | - | 0.210 | 0.273 | 0.450 | 0.286 |
Dividend Growth | - | -23.08% | -39.33% | 57.51% | - |
Gross Margin | 100.00% | 64.20% | 53.77% | 51.34% | 54.99% |
Operating Margin | 6.10% | 16.68% | 12.26% | 28.79% | 17.90% |
Profit Margin | 1.33% | 14.99% | 17.29% | 25.42% | 17.38% |
Free Cash Flow Margin | - | -3.15% | -35.84% | 25.57% | -9.60% |
EBITDA | 349.89 | 574.94 | 440.9 | 1,291 | 310.17 |
EBITDA Margin | 19.34% | 28.58% | 21.48% | 32.42% | 26.33% |
D&A For EBITDA | 239.49 | 239.49 | 189.28 | 144.73 | 99.32 |
EBIT | 110.4 | 335.46 | 251.62 | 1,146 | 210.85 |
EBIT Margin | 6.10% | 16.68% | 12.26% | 28.79% | 17.90% |
Effective Tax Rate | 74.37% | 12.67% | 16.43% | 13.93% | 10.50% |
Revenue as Reported | - | 2,012 | 2,053 | 3,981 | 1,178 |
Advertising Expenses | - | 31.66 | 36.49 | 187.69 | 23.15 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.